Label Image For 2mg (Doxazosin 2mg)
Doxazosin Mesylate
Product Images NDC 53808-1017
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin Mesylate (NDC 53808-1017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Doxazosin Mesylate)
Table 1 (Feea8d72 5781 46d5 831d 855f478c704d 02)
The text is a table containing different studies on the effectiveness of CARDURA in placebo-controlled trials. These studies analyzed the change in symptom score, modified Bojarsky questionnaire change, and maximum flow rate in patients with BPH. The results show that CARDURA was more effective than a placebo in reducing symptoms and improving the maximum flow rate. The text also includes statistical data, such as the mean, baseline, and standard deviation.*
Figure 1 (Study 1)
This is a chart that shows the mean change in total symptoms score and mean increase in maximum urinary flow rate (measured in mUsec) from baseline in a group of 50 patients taking CARDURA. The chart shows the change over a treatment duration of up to 12 weeks, with doxazosin titration to a maximum of 8 mg. There are statistical significance indicators shown for comparisons between treatment groups and baseline.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
